Duloxetine 60 mg was found efficacious for chronic low back pain

Primary tabs

Duloxetine 60 mg was found efficacious for chronic low back pain

According to a recently published post hoc analysis in the Journal dove press, the overall response of the patients who treated with Duloxetine to treat chronic low back pain showed was presented by the early pain reduction. Duloxetine, an SSNRI (selective serotonin and norepinephrine reuptake inhibitor) manifested significant efficiency for chronic low back pain (CLBP) management. However, the predictors of response regarding this are not clear.

The study aimed to determine predictors of response from four randomized, double-blind, placebo-controlled trials of Duloxetine for CLBP treatment. The dose of Duloxetine taken in these studies was 60 mg/day for 12–14 weeks. The portion of patients with ≥30% reduction in BPI (Brief Pain Inventory) average pain at 12–14 weeks was considered as the primary outcome. A comparison was done between the placebo and patients with ≥30% and ≥50% (secondary outcome) pain reduction in Duloxetine. The predictors examined for an overall response were age, sex, duration of CLBP, early improvement (≥15% pain reduction at Week 2), number of painful body sites according to the Michigan Body Map and baseline BPI average pain score. These all predictors were estimated for 95% confidence interval (CI) and relative risk (RR).
The Duloxetine-treated group showed obtained higher ≥30% (59.7%) and ≥50% pain reduction (48.6%) than placebo (47.8%; 35.1%, respectively with overall P < 0.001). An early improvement was correlated with higher probability of ≥30% (2.91) or ≥50% (3.24) pain reduction among Duloxetine-treated patients. The CLBP duration, baseline BPI average pain score and age subgroups showed similar response rates. Men achieved somewhat less ≥30% or ≥50% pain reduction than women. Patients with ≥2 painful sites showed higher ≥30% ( 1.40) or ≥50% (1.51) pain reduction as compared to patients with isolated CLBP (1.07 and 1.23, respectively). This exhibited that the early pain reduction is the major predictor for overall response.


Dove Press

Link to the source:


Original title of article:

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials


Levent Alev et al.

Therapeutic, Duloxetine, Low Back Pain, Lower Spine Region, Chronic, SSNRI, Post Hoc Analysis, Efficacy
Log in or register to post comments